What is AYA.AX stock and why is it moving

AYA.AX stock is Artrya Limited on the ASX. Moves reflect AI adoption hopes and technical momentum. Current price **A$3.38** reacts to trading liquidity, negative EPS **-0.17**, and investor attention on near-term milestones.

What is Meyka AI's grade and forecast for AYA.AX stock

Meyka AI rates AYA.AX **63.20 (B)** with a HOLD suggestion. Meyka AI's forecast model projects a yearly price of **A$7.90**, implying **133.70%** upside from **A$3.38**. Forecasts are model-based and not guarantees.

What are the main risks to an AYA.AX stock investment

Main risks include slow clinical adoption, regulatory and reimbursement delays, negative earnings, and valuation sensitive to revenue misses. Low average volume can increase price volatility on news.

When is Artrya's next earnings or report that traders should watch

Artrya's earnings announcement is scheduled for **24 Feb 2026**. Traders should watch revenue growth, contract updates for the Salix platform, and guidance that could change near-term price direction.

AU Stocks

A$3.38 after hours AYA.AX Artrya Limited ASX 09 Feb 2026: AI imaging catalyst

ByHuzaifa Zahoor February 9, 2026

AYA.AX stock opened the after-hours session at A$3.38 on 09 Feb 2026, a price that places Artrya Limited well below its 52-week high A$5.24 but above the 200-day average of A$2.34. Investors tracking AI health-imaging plays will note mixed signals: strong technical momentum and a small market capitalisation of A$370,556,400.00, against negative earnings per share of -0.17 and a negative price-to-earnings ratio of -19.24. This update covers valuation, technicals, Meyka AI grading, and model-led price forecasts that frame short- and medium-term opportunity and risk for AYA.AX stock.